Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
New Zealand introduced a new outer membrane vesicle vaccine in 2004 to combat an epidemic of group B meningococcal disease. An Independent Safety Monitoring Board oversaw intensive safety monitoring, which included hospital surveillance, health professional reporting (passive and active) and mortality monitoring. With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine's safety.
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand. anne_mcnicholas@moh.govt.nz
Anne
A
McNicholas
Yvonne
Y
Galloway
Paul
P
Stehr-Green
Stewart
S
Reid
Sarah
S
Radke
Kerry
K
Sexton
Charlotte
C
Kieft
Claire
C
Macdonald
Jocelyn
J
Neutze
Ross
R
Drake
Dorothy
D
Isaac
Mary
M
O'Donnell
Michael
M
Tatley
Philipp
P
Oster
Jane
J
O'Hallahan
D006801:Humans; D007115:Immunization Schedule; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D009520:New Zealand / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000639:trends; D016896:Treatment Outcome
D022401:Meningococcal Vaccines